報價延遲最少15分鐘:2025/06/02 07:31 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.46 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.62/4.40
|
|
企業價值
2.12B
|
| 資產負債 |
|
每股賬面淨值
12.55
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
714.73M
|
|
每股收益
9.44
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX(pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |